A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Clinical trial NCT07226986 · RECRUITING

Trial details

NCT number: NCT07226986
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

Start date: 2025-12-05
Primary completion: 2028-07-10
Enrollment: 123

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.